Evolution of Hematological Parameters in HIV-1-Infected Patients With and Without Thalassemia Carriages During Highly Active Antiretroviral Therapy

REFERENCES

• Curkendall SM, Richardson JT, Emons MF, Fisher AE, Everhard F. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med. 2007;8:483–490.
   PubMed Web of Science ®Google Scholar
• Kumarasamy N, Venkatesh KK, Cecelia AJ, et al. Spec-trum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS. 2008;22:337–344.
   PubMed Web of Science ®Google Scholar
• Moyle G, Sawyer W, Law M, Amin J, Hill A. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, compara-tive studies. Clin Ther. 2004;26:92–97.
   PubMed Web of Science ®Google Scholar
• Eyer-Silva WA, Arabe J, Pinto JF, Morais-De-Sa CA. Macrocytosis in patients on stavudine. Scand J Infect Dis. 2001;33:239–240.
   PubMed Web of Science ®Google Scholar
• Geene D, Sudre P, Anwar D, Goehring C, Saaidia A, Hirschel B. Causes of macrocytosis in HIV-infected patients not treated with zidovudine. Swiss HIV Cohort Study. J Infect. 2000;40:160–163.
   PubMed Web of Science ®Google Scholar
• Khawcharoenporn T, Shikuma CM, Williams AE, Chow DC. Lamivudine-associated macrocytosis in HIV-infected patients. Int J STD AIDS. 2007;18:39–40.
   PubMed Web of Science ®Google Scholar
• Levine AM, Berhane K, Masri-Lavine L, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2001;26:28–35.
   PubMed Web of Science ®Google Scholar
• Moyle G. Anaemia in persons with HIV infection: prog-nostic marker and contributor to morbidity. AIDS Rev. 2002;4:13–20.
   PubMedGoogle Scholar
• Semba RD, Shah N, Klein RS, Mayer KH, Schuman P, Vlahov D. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis. 2002;34:260–266.
   PubMed Web of Science ®Google Scholar
• Boudes P, Balloul E, Sobel A. [Tolerance of zidovu-dine in patients with beta-thalassemia]. Presse Med. 1989;18:777.
   PubMed Web of Science ®Google Scholar
• Vittecoq D, Delabesse E, Bary M, Girot R, Maier Redelsperger N, Bach JF. Poor tolerance of zidovudine in an HIV-asymptomatic patient with alpha-thalassemia. Am J Med. 1991;91:100–102.
   PubMed Web of Science ®Google Scholar
• Fucharoen S, Winichagoon P. Thalassemia in South-East Asia: problems and strategy for prevention and control. Southeast Asian J Trop Med Public Health. 1992;23:647–655.
   PubMedGoogle Scholar
• Fucharoen S, Winichagoon P. Hemoglobinopathies in Southeast Asia: molecular biology and clinical medicine. Hemoglobin. 1997;21:299–319.
   PubMed Web of Science ®Google Scholar
• Tanphaichitr VS, Mahasandana C, Suvatte V, Yodthong S, Pung-amritt P, Seeloem J. Prevalence of hemoglobin E, alpha-thalassemia and glucose-6-phosphate dehydroge-nase deficiency in 1,000 cord bloods studied in Bangkok. Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:271–274.
   PubMedGoogle Scholar
• Tienthavorn V, Pattanapongsthorn J, Charoensak S, Sae-Tung R, Charoenkwan P, Sanguansermsri T. Preva-lence of thalassemia carriers in Thailand. Thai J Hematol Transfus Med. 2006;16:307–312.
   PubMed Web of Science ®Google Scholar
• Pornprasert S, Leechanachai P, Klinbuayaem V, et al. Effect of hematological alterations on thalassemia investigation in HIV-1 infected Thai patients receiving antiretroviral treat-ment. HIV Med. 2008;9:660–666.
   PubMed Web of Science ®Google Scholar
• Mirasena S, Shimbhu D, Sanguansermsri M, Sanguansermsri T. Detection of beta-thalassemia muta-tions using a multiplex amplification refractory mutation system assay. Hemoglobin. 2008;32:403–409.
   PubMed Web of Science ®Google Scholar
• Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17:2503–2516.
   PubMed Web of Science ®Google Scholar
• Old J, Traeger-Synodinos J, Galanello R, Petrou M, Angastiniotis M. Prevention of Thalassemias and Other Haemoglobin Disorders. Volume 2: Laboratory Methods. 1st ed. Nicosia, Cyprus: Team up Creations; 2005.
   Google Scholar
• Bowden DK, Vickers MA, Higgs DR. A PCR-based strat-egy to detect the common severe determinants of alpha thalassaemia. Br J Haematol. 199281: 104–108.
   Google Scholar
• Chanprapaph P, Tongsong T, Wanapirak C, Sirichoti-yakul S, Sanguansermsri T. Prenatal diagnosis of alpha-thalassemia-1 (SEA type) by chorionic villus sampling. J Med Assoc Thai. 2002;85:1049–1053.
   PubMedGoogle Scholar
• Liu YT, Old JM, Miles K, Fisher CA, Weatherall DJ, Clegg JB. Rapid detection of alpha-thalassaemia deletions and alpha-globin gene triplication by multiplex polymerase chain reactions. Br J Haematol. 2000;108:295–299.
   PubMed Web of Science ®Google Scholar
• Huang SS, Barbour JD, Deeks SG, et al. Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis. 2000;30:504–510.
   PubMed Web of Science ®Google Scholar
• Semba RD, Shah N, Klein RS, et al. Highly active antiretroviral therapy associated with improved anemia among HIV-in-fected women. AIDS Patient Care STDS. 200115: 473–480.
   Google Scholar
• Berhane K, Karim R, Cohen MH, et al. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2004;37:1245–1252.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS. 1999;13:943–950.
   PubMed Web of Science ®Google Scholar
• Altinbas A, Ozkaya G, Buyukasik Y, Unal S. [Rapid development of anemia in a HIV-positive patient with alpha-thalassemia after zidovudine therapy]. Mikrobiyol Bul. 2007;41:473–476.
   PubMed Web of Science ®Google Scholar
• Isgro A, Mezzaroma I, Aiuti A, et al. Recovery of hematopoi-etic activity in bone marrow from human immunodefi-ciency virus type 1-infected patients during highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2000;16:1471–1479.
   PubMed Web of Science ®Google Scholar
• Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:315–319.
   PubMed Web of Science ®Google Scholar